buyModerate cluster of 4
Foresite Capital Management IV, LLC bought $5.0M of KNTE
owner at Kinnate Biopharma Inc.. 1,780,000 shares at an average of $2.80, traded May 8, 2023, filed May 10, 2023.
Conviction score
57Value
$5.0M
1,780,000 shares
Holdings after
520,711
+90% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +25Trade size$5.0M at market
- +10Relative to holdingsHoldings up 90%
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-23-028527, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 8, 2023 | POpen-market purchase Common Stockindirect: See Footnote | +1,550,956 | $2.80 | $4.3M | 3,525,957 | May 10, 2023 |
| May 8, 2023 | POpen-market purchase Common Stockindirect: See Footnote | +229,044 | $2.80 | $641k | 520,711 | May 10, 2023 |
Related signals
Other insiders at Kinnate Biopharma Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 75Notable | Kinnate Biopharma Inc. | James B. Tananbaum director, owner | $5.0M 1,780,000 shares | +90% | |
| 65Notable | Kinnate Biopharma Inc. | Carl L Gordon director, owner | $4.1M 1,460,932 shares | +184% | |
| 65Notable | Kinnate Biopharma Inc. | Orbimed Advisors LLC director, owner | $4.1M 1,460,932 shares | +184% | |
| 60Notable | Kinnate Biopharma Inc. | Carl L Gordon director, owner | $3.7M 1,405,168 shares | +255% | |
| 60Notable | Kinnate Biopharma Inc. | Orbimed Advisors LLC director, owner | $3.7M 1,405,168 shares | +255% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.